URL | Priority | Change frequency | Last modified (GMT) |
---|---|---|---|
https://beyondspringpharma.com/beyondspring-presents-efficacy-safety-data-from-a-phase-2-study-of-pembrolizumab-plus-plinabulin-docetaxel-in-metastatic-nsclc-after-progressing-on-first-line-immune-checkpoint-inhibitors-at-2025/ | 20% | Monthly | 2025-06-03 06:53 |